Develops new methods for producing medical-grade lead-212. This rare isotope offers promising perspectives to fight, notably, ovarian, pancreatic, colon, prostate, breast and other cancers.
Details: Areva Med is an AREVA subsidiary working on the research against the cancer. By developing innovative processes to produce lead-212, Areva Med contributes to the fight against the cancer. This rare isotope offers promising perspectives to fight, notably, ovarian, pancreatic, colon, prostate, breast and other cancers. Areva Med has two missions: Industrialize the production of the lead-212 and Develop effective therapies to fight the cancer. The treatment by alpha radioimmunotherapy shows great potential to fight certain fatal diseases like breast, ovarian, pancreatic, prostate and colon cancer. The medical subsidiary of AREVA leads experiments to extract rare isotope through its Research and Development programs.
Alpha Radioimmunotherapy works by binding an isotope, such as lead-212, to a monoclonal antibody. Using the body's own antigens, this treatment targets only cancer cells and destroys them. It shows great promise for the treatment of numerous types of cancers, such as pancreatic, ovarian, melanoma, and others that do not respond efficiently to existing treatments. Alpha radioimmunotherapy (alpha RIT) is a powerful anticancer therapy that targets cancerous cells without affecting the body's healthy normal cells. Lead-212 (212Pb) is a rare isotope that forms part of the thorium-228 decay chain. It shows great potential for use in advanced treatments for diseases such as cancer.
URL: www.areva.com
Category: Cancer
|
(1 votes)